FDA Approves MYCOPHENOLATE MOFETIL — ONESOURCE SPECIALTY PHARMA LIMITED
ONESOURCE SPECIALTY PHARMA LIMITED announced the approval of intravenous mycophenolate mofetil under ANDA 216390, which could strengthen the biologic immunosuppressant market by expanding access to cost-effective alternatives. This launch diversifies Onesource's product portfolio and capitalizes on strong demand in kidney transplant and autoimmune patient populations.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed